Cystatin C in renal dysfunction and identification of risk factors in people aged 25 to 29 in the City of Jipijapa
DOI:
https://doi.org/10.62305/biosana.v5i4.728Keywords:
diagnosis; hypertension; prevention; kidneys; riskAbstract
Cystatin C has been established as a reliable marker for the early detection of renal dysfunction due to its stability and high sensitivity. On the other hand, renal dysfunction is the inability of the kidneys to perform their normal blood filtering functions. The purpose of the study was to evaluate cystatin C levels in people aged 25 to 29 in the city of Jipijapa. The methodology was observational, descriptive, and cross-sectional. The results obtained showed a low prevalence of diabetes, with only 2% of the sample affected, high blood pressure in 12%, overweight or obesity being more prevalent in men (20%) than women (2%), and cardiovascular and autoimmune diseases being uncommon, affecting only 4%. Tobacco consumption is low, with 8% of smokers, and only 2% have been diagnosed with kidney disease. Cystatin C levels are normal in 32% of men and 56% of women. Based on cystatin C values, 32% of men have normal kidney function and 4% have severely reduced kidney function. On the other hand, in women, 56% are normal and 8% have a severe decrease in kidney function. It was concluded that the analysis suggests that elevated cystatin C levels and the presence of kidney failure are significantly related to a history of cardiovascular disease and a previous diagnosis of kidney disease.
Downloads
References
Castro J, Chonillo N, Guiracocha K, Indio N. (2025). Cystatin C and diabetes mellitus as risk factors in renal dysfunction. MQRInvestigar. 2025;9(1):41-51.
López S, Robles J. (2020). Risk factors and lifestyle factors associated with kidney disease. Médica del Instituto Mexicano del Seguro Social. 2020;58(3).
Aguilera A, Albarracin L, Castillo D, Bueno J, et al. (2020). Cistatina C vs marcadores convencionais da função renal: uma atualização. Salud Uninorte. 2020;31(1):110-32.
García R. (2022). Information and consensus document for the detection and management of chronic kidney disease. Nefrología. 2022;42(3).
Barcia C, Zambrano J. (2024). Acute renal failure: epidemiology, diagnostic tests, and prevention measures at the global level. MQR Investigar. 2024;8(1).
Zambrano J, Zambrano A. (2023). Serum proteins and electrolyte concentration in patients with chronic kidney disease. Pentaciencias. 2023;5(2).
Avila M, Mina J. (2023). Cystatin C and stages of kidney damage in adults at a private laboratory in the city of Jipijapa. MQRInvestigar. 2023;7(4).
Huidobro J, Guzman A. (2021). Use of cystatin C as a biomarker to estimate glomerular filtration rate. Medica Chile. 2021;149(1):98-102.
Gutierres A, De la Torres A. (2024). Cystatin C as a marker of kidney damage in patients with type II diabetes mellitus. PENTACIENCIAS. 2024;6(3):333-4.
Kimn Ch, Han K, Choi H et al. (2020). Association of Body Mass Index and Waist Circumference with All-Cause Mortality in Hemodialysis Patients. J Clin Med. 2020;9(5):1289.
Vanhoutte T, Sprangers B. (2022). Serum cystatin C level can be used to estimate GFR in patients with solid tumors: Moderator Commentary. Journal of Onco-Nephrology. 2022;6(3).
Delgado M, Bueno A. (2023). La obesidad como factor de riesgo en la enfermedad renal crónica. Revisión bibliográfica. MQR Investigar. 2023;7(3).
García R, Bover J, Segura J et al. (2022). Documento de información y consenso para la detección y manejo de la enfermedad renal crónica. NEFROLOGIA. 2022;42(3).
Pottel H, Delanaye P, Cavalier E. (2024). Exploring Renal Function Assessment: Creatinine, Cystatin C, and Estimated Glomerular Filtration Rate Focused on the European Kidney Function Consortium Equation. Ann Lab Med. 2024;44(2):135-43.
Benoit S, Ciccia E, Devarajan P. (2021). Cystatin C as a biomarker of chronic kidney disease: latest developments. Expert Rev Mol Diagn. 2021;20(10):1019–26.
Latcha S. (2022). Serum cystatin C level can be used to estimate GFR in patients with solid tumors: CON. Journal of Onco-Nephrology. 2022;6(3).
Yun H, Smith A, DeBacker K, Pai M. (2023). Estimated glomerular filtration rate with and without race for drug dosing: Cystatin C vs. serum creatinine. Br J Clin Pharmacol. 2023;89:1207–10.
Zadabbas H, Golbashirzadeh M, Moradzadegan A. (2024). Explorando a cistatina C como um indicador precoce de nefropatia diabética em fase terminal em pacientes com diabetes tipo 2. Endocrinology and Metabolism. 2024;14(5):240-9.
Avila M, Mora M, Bernal A, Paniagua R. (2025). The Metabolism of Creatinine and Its Usefulness to Evaluate Kidney Function and Body Composition in Clinical Practice. Biomolecules. 2025;15(1):41.
Fang Y, Huang W, Wang Ch, Lin Ch. (2025). Associations of Serum Cystatin C, DNAm Cystatin C, Renal Function, and Mortality in U.S. Adults. Life. 2025;15(1):13.
Khang R, Lee M, Yi D, Kang Y. (2023). The Ratio of Estimated Glomerular Filtration Rate Based on Cystatin C and Creatinine Reflecting Cardiovascular Risk in Diabetic Patients. Cardiovascular Risk/Epidemiology. 2023;47(3):415-25.
Avgoustou E, Tzivaki I, Diamantopoulou G et al. (2025). Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment. Diagnostics. 2025;15(2).
Choi J, Cho Y, Yeoup S et al. (2020). The Association between Obesity Phenotypes and Early Renal Function Decline in Adults without Hypertension, Dyslipidemia, and Diabetes. Korean J Fam Med. 2020;40(3):176–81.
Amatruda JG, Katz R, Peralta CA, Estrella MM, Sarathy H, Fried LF, et al. Association of non‐steroidal anti‐inflammatory drugs with kidney health in ambulatory older adults. Journal of the American Geriatrics Society. 2021;69(3):726-34.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 BIOSANA Health Scientific Journal. ISSN 2960-8481
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
